Cargando…
The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388337/ https://www.ncbi.nlm.nih.gov/pubmed/34465966 http://dx.doi.org/10.4103/iju.IJU_542_20 |
_version_ | 1783742619057127424 |
---|---|
author | Tripathy, Sambit |
author_facet | Tripathy, Sambit |
author_sort | Tripathy, Sambit |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-8388337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-83883372021-08-30 The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer Tripathy, Sambit Indian J Urol Uroscan Wolters Kluwer - Medknow 2021 2021-07-01 /pmc/articles/PMC8388337/ /pubmed/34465966 http://dx.doi.org/10.4103/iju.IJU_542_20 Text en Copyright: © 2021 Indian Journal of Urology https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Uroscan Tripathy, Sambit The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer |
title | The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer |
title_full | The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer |
title_fullStr | The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer |
title_full_unstemmed | The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer |
title_short | The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer |
title_sort | aramis trial: why darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer |
topic | Uroscan |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388337/ https://www.ncbi.nlm.nih.gov/pubmed/34465966 http://dx.doi.org/10.4103/iju.IJU_542_20 |
work_keys_str_mv | AT tripathysambit thearamistrialwhydarolutamideisbetterthanapalutamideandenzalutamideinnonmetastaticcastrationresistantprostatecancer AT tripathysambit aramistrialwhydarolutamideisbetterthanapalutamideandenzalutamideinnonmetastaticcastrationresistantprostatecancer |